Opinion|Videos|January 13, 2025
Diagnostic Tools for PPD
Panelists discuss how to diagnose postpartum depression (PPD) promptly using tools such as standardized screening questionnaires, especially in busy or resource-limited settings, and explore strategies to enhance PPD screening in underserved and minority populations in which symptoms may be underreported, while also considering the role of the case study patient’s family history in identifying her PPD symptoms.
Advertisement
Episodes in this series
Advertisement
Related to this article
Veterans younger than 30 starting antidepressants, and anyone coprescribed opioids and benzodiazepines, will need to sign consent forms starting in 2027.
Policy shifts have opened the door to telehealth buprenorphine for pregnant and postpartum women with OUD, but research, guidelines, and state policy lag behind.
Overlooking how hearing loss and sign language shape the Mental Status Examination can make language deprivation look like psychosis, authors warn.
Phase 3 psilocybin and LSD data plus new FDA guidance fuel a depression boom—yet clinics still wrestle with dosing time, cost, access.
Explore Q3 2026 psych pipeline highlights—wins, setbacks, top disorders, and breakthrough ADHD, TRD, schizophrenia and Alzheimer therapies to watch.
The menopause transition carries a 2-fold increased risk of depression, and an expert explains how clinicians can screen for it, tell it apart from other conditions, and treat it.
Check out our pipeline updates from September!
Don't miss out on these CME articles! Test your knowledge here.
Advertisement
Advertisement
Trending on Psychiatric Times
1
September 2026 in Review: Updates on the Psychiatric Treatment Pipeline, FDA News
2
Rapid Antidepressants and Suicide Risk: What Do We Really Know?
3
Why Diagnosis Remains Psychiatry's Hardest Task in MDD
4
ACNP Position Paper Lays Out Roadmap for Biomarker-Guided Psychiatric Drug Trials
5